IPO Year: 2016
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/18/2025 | $385.00 | Overweight | Barclays |
| 4/7/2025 | $312.00 | Outperform | RBC Capital Mkts |
| 3/3/2025 | $207.00 → $320.00 | Neutral → Buy | BofA Securities |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Barclays initiated coverage of BeOne Medicines with a rating of Overweight and set a new price target of $385.00
RBC Capital Mkts initiated coverage of BeiGene with a rating of Outperform and set a new price target of $312.00
BofA Securities upgraded BeiGene from Neutral to Buy and set a new price target of $320.00 from $207.00 previously
144 - BeOne Medicines Ltd. (0001651308) (Subject)
144 - BeOne Medicines Ltd. (0001651308) (Subject)
144 - BeOne Medicines Ltd. (0001651308) (Subject)
144 - BeOne Medicines Ltd. (0001651308) (Subject)
8-K - BeOne Medicines Ltd. (0001651308) (Filer)
8-K - BeOne Medicines Ltd. (0001651308) (Filer)
10-Q - BeOne Medicines Ltd. (0001651308) (Filer)
8-K - BeOne Medicines Ltd. (0001651308) (Filer)
144 - BeOne Medicines Ltd. (0001651308) (Subject)
144 - BeOne Medicines Ltd. (0001651308) (Subject)
Fastest customizable press release news feed in the world
Study met its primary endpoint of overall response rate (ORR), demonstrating clinically meaningful responses in rare B-cell lymphoma with high unmet need BeOne to submit data to global regulatory authorities for their review and potential approval BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton's tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans t
Final analysis of RATIONALE-315 demonstrates clear overall survival benefit in perioperative setting in resectable non-small cell lung cancer Broad EU label with nine approved indications in solid tumors, including five in lung cancer, highlights TEVIMBRA's therapeutic range and strong clinical profile throughout the care continuum BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced that the European Commission (EC) has approved TEVIMBRA (tislelizumab), in combination with platinum-containing chemotherapy as neoadjuvant treatment followed by TEVIMBRA monotherapy as adjuvant treatment, for adult patients with resectable non-small cell
BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced it will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, with a fireside chat at 1:50 p.m. EDT. The live webcast of this event can be accessed from the investors section of the Company's website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. An archived webcast will be available on the Company's website. About BeOne Medicines BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and
Royalty Pharma to acquire rights to BeOne's royalties on IMDELLTRA® (tarlatamab-dlle) worldwide (ex-China) sales for up to $950 million IMDELLTRA is a first-in-class DLL-3 targeting bispecific T-cell engager, indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced it has entered into an agreement to sell its royalty rights on the worldwide sales, excluding China, of Amgen's IMDELLTRA® (tarlatamab-dlle) for up to $950 million to Royalty Pharma (NASDAQ:RPRX). Under the term
Tablets will advance treatment simplicity and convenience to meet patient needs across Europe BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced that the European Commission has approved a new film-coated tablet formulation of BRUKINSA® (zanubrutinib) for all approved indications. "Developed to meet the real-world needs of patients, the new BRUKINSA tablet formulation aims to simplify treatment, reduce pill burden, and enhance ease of administration, reflecting our continuous focus on patient-centered innovation," said Giancarlo Benelli, Senior Vice President and Head of Europe, BeOne. "With more than 200,000 patients treated globall
Second quarter total revenues increased 42% to $1.3 billion versus second quarter 2024 Global BRUKINSA revenues increased 49% to $950 million versus second quarter 2024 Reported diluted GAAP Earnings per American Depositary Share (ADS) of $0.84, non-GAAP diluted Earnings per ADS of $2.25 Anticipate 20+ milestones in next 18 months across hematology and solid tumor pipeline BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced financial results and corporate updates from the second quarter of 2025. "Our strong second quarter performance reinforces our trajectory as a global oncology powerhouse and underscores our proven abilit
Decision highlights the promise of BGB-16673, an investigational and potentially first-in-class BTK degrader designed to overcome resistance and deepen responses in B-cell malignancies BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation to the Company's investigational Bruton's tyrosine kinase (BTK) degrader, BGB-16673, for the treatment of patients with Waldenstrom's macroglobulinemia (WM) previously treated with a BTK inhibitor. "This is the Company's first PRIME designation, marking a milestone for BeOne and providing early and enhanced inte
Recommendation based on Phase 3 RATIONALE-315 study, in which TEVIMBRA demonstrated clinically meaningful and statistically significant improvement in event-free survival and major pathological response If approved, the expanded label builds on TEVIMBRA's momentum in lung cancer with EU approvals already in NSCLC and SCLC indications across both first- and second-line settings BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA® (tislelizumab), in combination with platinum-containi
BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, will report its second quarter 2025 financial results on Wednesday, August 6, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company's website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Comp
New indication based on results of RATIONALE-309 study demonstrating statistically significant improvement in progression-free survival Second approval for TEVIMBRA in the European Union this year BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced that the European Commission has approved TEVIMBRA® (tislelizumab), in combination with gemcitabine and cisplatin, for the first-line treatment of adult patients with metastatic or recurrent nasopharyngeal carcinoma (NPC), not amenable to curative surgery or radiotherapy. Nasopharyngeal carcinoma is a rare cancer in which malignant cells form in the nasopharynx, the upper part of the throat
Live finance-specific insights
Second quarter total revenues increased 42% to $1.3 billion versus second quarter 2024 Global BRUKINSA revenues increased 49% to $950 million versus second quarter 2024 Reported diluted GAAP Earnings per American Depositary Share (ADS) of $0.84, non-GAAP diluted Earnings per ADS of $2.25 Anticipate 20+ milestones in next 18 months across hematology and solid tumor pipeline BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced financial results and corporate updates from the second quarter of 2025. "Our strong second quarter performance reinforces our trajectory as a global oncology powerhouse and underscores our proven abilit
First quarter 2025 total revenues increased 49% to $1.1 billion with BRUKINSA® (zanubrutinib) global sales increasing 62% to $792 million on strong demand growth versus first quarter 2024 Achieved GAAP profitability and significantly improved operating cash flow Advanced late-stage hematology and solid tumor pipelines with plan to host Investor R&D Day on June 26 Secured shareholder approval to rename the Company to BeOne Medicines Ltd. and redomicile to Switzerland BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that will change its name to BeOne Medicines, Ltd., today announced financial results and corporate updates from the first quarter 2025.
BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its first quarter 2025 financial results on Wednesday, May 7, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The conference call will be webcast live and a link to the webcast can be accessed from the investors section of the Company's website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the schedul
Total global revenues of $1.1 billion and $3.8 billion for the fourth quarter and full year, increases of 78% and 55%, respectively; narrowed GAAP operating loss and achieved full-year positive non-GAAP operating income Global BRUKINSA revenues of $828 million and $2.6 billion for the fourth quarter and full year, increases of 100% and 105%, respectively; progressed pivotal-stage programs for BCL2 inhibitor sonrotoclax and BTK CDAC BGB-16673 Advanced six and 13 New Molecular Entities (NMEs) into the clinic in the fourth quarter and full year, respectively; anticipate multiple data readouts for innovative solid tumor programs in 1H 2025 Full year 2025 revenue guidance of $4.9 billi
BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with BeiGene management at 8:00 a.m. ET. The conference call will be webcast live and a link to the webcast can be accessed from the investors section of BeiGene's website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. To ensure a timely connection, it is recommended that participants register at least 15 min
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - BeOne Medicines Ltd. (0001651308) (Issuer)
4 - BeOne Medicines Ltd. (0001651308) (Issuer)
4 - BeOne Medicines Ltd. (0001651308) (Issuer)
4 - BeOne Medicines Ltd. (0001651308) (Issuer)
4 - BeOne Medicines Ltd. (0001651308) (Issuer)
4 - BeOne Medicines Ltd. (0001651308) (Issuer)
4 - BeOne Medicines Ltd. (0001651308) (Issuer)
4 - BeOne Medicines Ltd. (0001651308) (Issuer)
4 - BeOne Medicines Ltd. (0001651308) (Issuer)
4 - BeOne Medicines Ltd. (0001651308) (Issuer)